Literature DB >> 1471883

Psychological effects of sodium valproate and carbamazepine in epilepsy.

G Stores1, P L Williams, E Styles, Z Zaiwalla.   

Abstract

Information from standardised tests of intelligence, school attainments, attention, memory and visuomotor function, together with parent and teacher questionnaire information about various aspects of behaviour, was obtained for 63 schoolchildren with newly diagnosed epilepsy before treatment with sodium valproate or carbamazepine, and again at intervals for a total period of 12 months. The same information was collected on 47 matched controls. The children with epilepsy represented those under non-specialised paediatric care. The result showed that both drugs were effective in most cases at modest dosage without causing notable psychological effects 12 months into treatment. Modest and temporary adverse cognitive effects seen earlier in treatment could have been the result of uncontrolled seizure discharge. Improved function was the same in children with epilepsy and controls. Some psychological abnormalities in the children with epilepsy were evident before treatment suggesting early unwanted effects of the epileptic process itself.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1471883      PMCID: PMC1793785          DOI: 10.1136/adc.67.11.1330

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  28 in total

1.  ON THE NATURE OF THE "ABSENCE" IN CENTRENCEPHALIC EPILEPSY: A STUDY OF SOME BEHAVIORAL, ELECTROENCEPHALOGRAPHIC AND AUTONOMIC FACTORS.

Authors:  A F MIRSKY; J M VANBUREN
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1965-03

2.  Prediction of adult height from height, bone age, and occurrence of menarche, at ages 4 to 16 with allowance for midparent height.

Authors:  J M Tanner; R H Whitehouse; W A Marshall; B S Carter
Journal:  Arch Dis Child       Date:  1975-01       Impact factor: 3.791

3.  Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development.

Authors:  A Prader; R H Largo; L Molinari; C Issler
Journal:  Helv Paediatr Acta Suppl       Date:  1989-06

4.  Estrogen treatment of tall girls.

Authors:  E J Schoen; I L Solomon; O Warner; J Wingerd
Journal:  Am J Dis Child       Date:  1973-01

5.  A comparison between Greulich-Pyle and Tanner-Whitehouse assessments of skeletal maturity.

Authors:  A F Roche; G H Davila; S L Eyman
Journal:  Radiology       Date:  1971-02       Impact factor: 11.105

6.  Critical analysis of height reduction in oestrogen-treated tall girls.

Authors:  W Sorgo; K Scholler; F Heinze; E Heinze; W M Teller
Journal:  Eur J Pediatr       Date:  1984-09       Impact factor: 3.183

7.  Cognitive function in adult epileptic patients established on anticonvulsant monotherapy.

Authors:  R A Gillham; N Williams; K D Wiedmann; E Butler; J G Larkin; M J Brodie
Journal:  Epilepsy Res       Date:  1990-12       Impact factor: 3.045

8.  Theoretical growth evaluation (TGE). A computerized screening system for growth disorders.

Authors:  M Zachmann; P Nessi
Journal:  Clin Pediatr (Phila)       Date:  1984-11       Impact factor: 1.168

9.  Side effects of sodium valproate in monotherapy controlled by plasma levels: a study in 88 pediatric patients.

Authors:  J L Herranz; R Arteaga; J A Armijo
Journal:  Epilepsia       Date:  1982-04       Impact factor: 5.864

10.  Girls with fragile X syndrome: physical and neurocognitive status and outcome.

Authors:  R J Hagerman; C Jackson; K Amiri; A C Silverman; R O'Connor; W Sobesky
Journal:  Pediatrics       Date:  1992-03       Impact factor: 7.124

View more
  17 in total

Review 1.  Anticonvulsants and breast feeding: a critical review.

Authors:  B Bar-Oz; I Nulman; G Koren; S Ito
Journal:  Paediatr Drugs       Date:  2000 Mar-Apr       Impact factor: 3.022

2.  The cognitive impact of antiepileptic drugs.

Authors:  Clare M Eddy; Hugh E Rickards; Andrea E Cavanna
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

3.  Growing up with epilepsy: a two-year investigation of cognitive development in children with new onset epilepsy.

Authors:  Bruce P Hermann; Jana E Jones; Raj Sheth; Monica Koehn; Tara Becker; Jason Fine; Chase A Allen; Michael Seidenberg
Journal:  Epilepsia       Date:  2008-09-10       Impact factor: 5.864

Review 4.  Starting at the beginning: the neuropsychological status of children with new-onset epilepsies.

Authors:  Bruce P Hermann; Jana E Jones; Daren C Jackson; Michael Seidenberg
Journal:  Epileptic Disord       Date:  2012-03       Impact factor: 1.819

Review 5.  A comparative review of the adverse effects of anticonvulsants in children with epilepsy.

Authors:  S J Wallace
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

6.  Cognitive function and mood after profound nocturnal hypoglycaemia in prepubertal children with conventional insulin treatment for diabetes.

Authors:  K A Matyka; L Wigg; S Pramming; G Stores; D B Dunger
Journal:  Arch Dis Child       Date:  1999-08       Impact factor: 3.791

Review 7.  Cognitive and magnetic resonance volumetric abnormalities in new-onset pediatric epilepsy.

Authors:  Bruce P Hermann; Jana Jones; Raj Sheth; Michael Seidenberg
Journal:  Semin Pediatr Neurol       Date:  2007-12       Impact factor: 1.636

8.  Sleep and psychological disturbance in nocturnal asthma.

Authors:  G Stores; A J Ellis; L Wiggs; C Crawford; A Thomson
Journal:  Arch Dis Child       Date:  1998-05       Impact factor: 3.791

9.  Neuropsychological status at seizure onset in children: risk factors for early cognitive deficits.

Authors:  P S Fastenau; C S Johnson; S M Perkins; A W Byars; T J deGrauw; J K Austin; D W Dunn
Journal:  Neurology       Date:  2009-08-12       Impact factor: 9.910

10.  Behavioral impairments in rats with chronic epilepsy suggest comorbidity between epilepsy and attention deficit/hyperactivity disorder.

Authors:  Eduardo Pineda; J David Jentsch; Don Shin; Grace Griesbach; Raman Sankar; Andrey Mazarati
Journal:  Epilepsy Behav       Date:  2013-11-18       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.